TCG
CRL icon

Transcendent Capital Group’s Charles River Laboratories CRL Stock Holding History

Transcendent Capital Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$554 – 149
2024
Q4 		$554 Hold
3
– – ﹤0.01% 435
2024
Q3 		$591 Hold
3
– – ﹤0.01% 456
2024
Q2 		$620 Buy
+3
New +$680 ﹤0.01% 412

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Transcendent Capital Group's CRL Position: Q1 2025 in Review

Transcendent Capital Group sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 3 shares — an estimated $554 sold.

Transcendent Capital Group first reported a position in CRL in Q2 2024 and held it in 3 quarters. The position peaked at $620 in Q2 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Transcendent Capital Group reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Transcendent Capital Group sold 3 Charles River Laboratories shares in Q1 2025, an estimated $554.
  • Transcendent Capital Group first reported a position in Charles River Laboratories in Q2 2024 and held it in 3 quarters.
  • Transcendent Capital Group's Charles River Laboratories position peaked at $620 in Q2 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Transcendent Capital Group's 13F filing for Q1 2025, filed 2 May 2025.